Skip to main content

Table 4 Univariate analyses of the associations between FGFR polymorphisms and the response of neoadjuvant chemotherapy

From: Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients

Target Gene

Polymorphisms/Genotype

Nonresponders

N = 29(32%)

Responders

N = 61(68%)

OR (95% CI)

P

P HWE

FGFR1

rs2288696

    

0.014

 

C/C

25(86.2)

50(82.0)

Reference

1.000

 
 

C/T

1(3.4)

11(18.0)

1.00 (0.28–3.64)

0.999

 
 

T/T

3(10.3)

0(0)

0

0.615

 
 

Dominat model

4(13.8)

4(6.6)

0.73(0.21–2.52)

  
 

Recessive model

26(89.7)

61(100)

0

1.000

 
 

Alleles

     
 

C

51(87.9)

111(91.0)

Reference

0.344

 
 

T

7(12.1)

11(9.0)

0.57(0.18–1.82)

0.999

 

FGFR2

rs2981582

    

0.343

 

C/C

11(37.9)

31(50.8)

Reference

  
 

C/T

15(51.7)

21(34.4)

2.01(0.78–5.23)

0.151

 
 

T/T

3(10.3)

9(14.8)

0.94(0.22–4.11)

0.934

 
 

Dominat model

18(62.1)

30(49.2)

1.69(0.69–4.17)

0.254

 
 

Recessive model

26(89.7)

52(85.2)

1.50(0.37–6. 02)

0.567

 
 

Alleles

     
 

C

37(63.8)

83(68.0)

Reference

  
 

T

21(36.2)

39(32.0)

1.21(0.63–2.33)

0.573

 
 

rs1219648

    

0.700

 

A/A

9(31.0)

19(31.1)

Reference

  
 

A/G

16(55.2)

30(49.2)

1.13(0.42–3.06)

0.816

 
 

G/G

4(13.8)

12(19.7)

0.70(0.18–2.80)

0.618

 
 

Dominat model

20(69.0)

42(68.9)

1.01(0.39–2.61)

0.99

 
 

Recessive model

25(86.2)

49(80.3)

1.53(0.45–5.24)

0.498

 
 

Alleles

     
 

A

34(58.6)

68(55.7)

Reference

  
 

G

24(41.4)

54(44.3)

0.89(0.47–1.67)

0.715

 
 

rs2420946

    

0.377

 

T/T

1(3.4)

11(18.0)

Reference

  
 

C/T

18(62.1)

29(47.5)

6.83(0.81–57.45)

0.077

 
 

C/C

10(34.5)

21(34.4)

5.24(0.59–46.40)

0.137

 
 

Dominat model

28(96.6)

50(82.0)

6.16(0.76–50.24)

0.090

 
 

Recessive model

22(75.9)

54(88.5)

1.00 (0.39–2.53)

0.996

 
 

Alleles

     
 

T

20(34.5)

51(41.8)

Reference

  
 

C

38(65.5)

71(58.2)

1.37(0.71–2.61)

0.348

 
 

rs2981579

    

0.060

 

T/T

7(24.1)

18(29.5)

Reference

  
 

C/T

12(41.4)

24(39.3)

1.29(0.42–3.92)

0.659

 
 

C/C

10(34.5)

19(31.1)

1.35(0.42–4.32)

0.610

 
 

Dominat model

22(75.9)

43(70.5)

2.39(0.96–5.99)

0.062

 
 

Recessive model

26(89.7)

51()

0.86(0.34–2.20)

0.752

 
 

Alleles

     
 

T

26(44.8)

60(49.2)

Reference

  
 

C

32(55.2)

62(50.8)

1.19(0.64–2.23)

0.585

 
 

rs2981578

    

0.060

 

G/G

10(34.5)

34(55.7)

Reference

  
 

A/G

12(41.4)

20(32.8)

2.04(0.75–5.57)

0.164

 
 

A/A

7(24.1)

7(11.5)

3.40(0.96–12.02)

0.058

 
 

Dominat model

19(65.5)

27(44.3)

2.39(0.96–5.99)

0.062

 
 

Recessive model

22(75.9)

54(88.5)

0.41(0.13–1.30)

0.129

 
 

Alleles

     
 

G

32(55.2)

88(72.1)

Reference

  
 

A

26(44.8)

34(27.9)

2.10(1.10–4.03)

0.025*

 

FGFR3

rs743682

    

0.198

 

G/G

25(86.2)

49(80.3)

Reference

  
 

A/G

3(10.3)

11(18.0)

0.54(0.14–2.09)

0.368

 
 

A/A

1(3.4)

1(1.6)

1.96(0.12–32.67)

0.639

 
 

Dominat model

4(13.8)

12(19.7)

0.65(0.65–0.19)

0.498

 
 

Recessive model

27(93.1)

61(100)

0.47(0.03–7.74)

0.595

 
 

Alleles

     
 

G

53(91.4)

109(89.3)

Reference

  
 

A

5(8.6)

13(10.7)

0.79(0.27–2.34)

0.671

 

FGFR4

rs1966265

    

0.343

 

G/G

8(27.6)

12(19.7)

Reference

  
 

A/G

18(62.1)

22(36.1)

1.23(0.41–3.65)

0.713

 
 

A/A

3(10.3)

27(44.3)

0.17(0.04–0.74)

0.019*

 
 

Dominat model

21(72.4)

49(80.3)

1.16(0.64–1.80)

0.401

 
 

Recessive model

26(89.7)

34(55.7)

6.88(1.88–25.2)

0.004*

 
 

Alleles

     
 

G

34(58.6)

46(37.7)

Reference

  
 

A

24(41.4)

76(62.3)

0.43(0.23–0.81)

0.009*

 
  1. OR odds ratio, 95% CI 95% confidence interval, * A P value < 0.05 was considered ststistically significant
Back to article page